University of Hong

Company snapshot

University of Hong is a pharma organization headquartered in CN. Primary therapeutic focus areas include Early Childhood Caries, Acute Myeloid Leukemia, Influenza Virus Infection, Smoking Cessation, Influenza. NovaPharmaNews links 42 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: approved (13), phase 2 (10), phase 3 (6).

• 42 active pipeline program(s) linked via ClinicalTrials.gov.
• 42 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for University of Hong. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for University of Hong.

1. Jun 8, 2026 Clinical update

   TKC202505 — Unknown

2. Jun 8, 2026 Clinical update

   UW 22-704 — Unknown

3. Jun 8, 2026 Clinical update

   Trivalent live attenuated seasonal influenza vaccine — Approved

4. Jun 8, 2026 Clinical update

   TIV 2010/2011 influenza vaccine — Unknown

5. Jun 8, 2026 Clinical update

   sevelamer hydrochloride — Unknown

View all clinical trial activity →

• What is University of Hong?

  University of Hong is a pharma organization headquartered in CN. Primary therapeutic focus areas include Early Childhood Caries, Acute Myeloid Leukemia, Influenza Virus Infection, Smoking Cessation, Influenza. NovaPharmaNews links 42 clinical program(s), 0 drug profile(s), and 0

• Is University of Hong publicly traded?

  University of Hong appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does University of Hong develop or market?

  We link 71 drug profile(s) where University of Hong is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/the-university-of-hong-kong#company-drugs.

• What are the latest developments for University of Hong?

  In the last 12 months our linked public records show 42 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does University of Hong focus on?

  University of Hong focuses on Early Childhood Caries, Acute Myeloid Leukemia, Influenza Virus Infection based on our analysis of their pipeline programs and drug development activities.